National Events

Business Development Manager
(Avanti Polar Lipids-Adjuvants Portfolio)
Croda India Company Private Limited,
Navi Mumbai

Professor and Chairperson
University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh
US-Fulbright Fellow 2017-18

Dean, Faculty of Pharmaceutical Sciences &
Vice Principal, Poona College of Pharmacy
Bharati Vidyapeeth (Deemed University),
Pune

Prof. Krutika K Sawant is the Head, Pharmacy Department, (since 2-5-2017) and Dean, Faculty of Pharmacy (since Oct 2019), The Maharaja Sayajirao University of Baroda, Vadodara.
She obtained her B Pharm, M Pharm and Ph D from The M S University of Baroda.
Her Broad area of Specialization is Formulation and Development of Controlled and Novel Drug Delivery Systems.
She has more than 33 years of Teaching and Research Experience.
She has 1 Indian patent granted, 5 Book chapters, 110 Publications and nearly 80 Papers Presentations.
Prof Sawant has 4548 Citations with h-index of 36 and i10-index of 73.
She has guided 25 Ph D and 82 M Pharm students.
She is a Reviewer for more than 25 Scopus Indexed peer Reviewed International Journals. She is a Member of Board of Studies in Pharmacy and Faculty Board of MSUB and few other Universities.
She has acted as a Resource person for various Seminars, Workshops, Conferences and Staff Development programs.
She is a Member, Research Monitoring Committee / Doctoral Advisory Committee for Gujarat Technological University, Nirma University, CHARUSAT University, Dharamsinh Desai University, Parul University etc.
She has also acted as Examiner for B.Pharm., M.Pharm. and Ph.D. courses at various Colleges and Universities.

Professor Swati Biswas completed B. Pharm and M. Pharm from Jadavpur University, Kolkata, and earned a Ph.D. degree in 2008 from the Department of Pharmaceutical Sciences, Wayne State University, Detroit, Michigan. Later, she worked as a postdoctoral fellow at Wayne State University for one year and Northeastern University for four years. Professor Biswas joined BITS-Pilani Hyderabad as an Assistant Professor in 2013 and was later promoted to Associate Professor in 2018. Her current research interest includes drug delivery to cancer and the eye via nanoparticles systems such as liposomes, polymeric micelles, solid lipid nanoparticles, and inorganic nanoparticles. The lab is actively working on developing nanomedicines capable of executing multiple functions, such as combination drug delivery, chemo-photodynamic therapy, photothermal-chemotherapy, etc., for successful tumor regression. Prof. Biswas has 80 peer-reviewed publications in reputed journals, four book chapters, sixty conference proceedings, and ten patents (Indian and international) to her credit. Prof. Biswas received research supports from DST-Fast Track, DST-SERB, DBT-BioCARe, DST-Indo-Belarus, CSIR, ICMR-DHR, Daewoong Pharmaceuticals, Ltd, Hyderabad, Dr. Reddy’s Laboratory, Hyderabad, and Sun Pharmaceutical Advanced Research Company, Vadodara. Dr. Biswas has been featured among the world’s top 2 % scientists in the single year 2019 and 2020 in a publication of science-wise author databases by Stanford University. Dr. Biswas has recently been nominated as an Editorial Advisory Board Member of the Journal, ACS Molecular pharmaceutics for 2021-2023.

Dr. K. Rajeshwari, Founder and Managing Director of Bioklone Biotech Private Limited, Chennai, India is a scientist turned entrepreneur. She obtained her Ph.D from Indian Institute of Science (IISc), Bangalore, India. She was a Post-Doctoral Fellow at Thomas Jefferson University, Philadelphia, USA and a Visiting Fellow at Tata Institute of Fundamental Research (TIFR), Mumbai, India before inception of Bioklone in 2006. Rajeshwari has been a resource person for several Entrepreneurship development programmes and has been a mentor for aspiring and start-up entrepreneurs. In 2015, Entrepreneurship Development Institute of India (EDII), Gandhi Nagar, Gujarat, India under the Aegis of Department of
Science & Technology published Dr. Rajeshwari’s case study in the science and technology space of a book entitled “The Innovators-Stories of Hi-tech Entrepreneurs”.

Dr. SachinDubey is presently working with Ichnos Sciences, Switzerland as Deputy Director & Head of the Formulation, Analytical & Drug Product Development. His current responsibilities include designing & executing product development & characterization strategies for both early & late-stage products for Ichnos Biologics. Sachin earned his Ph.D. from the University of Geneva, Switzerland & has previously worked with Glenmark Pharmaceuticals, Switzerland &NovozymesBiopharma, Denmark. He has ~ 12 years of experience in biopharmaceutical formulation & combinational product development. Twelve products developed by him & his team are currently in different clinical trials, he has overseen the production of >75 drug product/diluent/diluent for clinical trial phases 1-3. He has extensive experience with regulatory submissions in the USA, EU & India and have 9 PCT patent applications, ~ 20 publications in high impact journals like JCR etc., 6 book chapters & ~ 60 presentations to his credit. He also has received 20 research awards including prestigious industry awards from Glenmark (Best innovation team – won twice), Merck (Innovation cup), Novartis (International bio-camp) & Swiss Society of Pharmaceutical Sciences (Best publication).

Dr Suneet Shukla is a pharmacist with Ph.D. in Molecular Pharmacology from Jawaharlal Nehru University, New Delhi, India. He completed his postdoctoral training at National Cancer Institute, NIH. He then joined FDA and has worked at the Office of Pharmaceutical Quality and the Office of Generic drugs where his responsibilities included the assessment of INDs, NDAs, ANDAs. Currently, he is working as Senior Pharmacologist at the Office of Clinical Pharmacology. DrShukla possesses years of highly specialized research and regulatory experience in PK/PD data analysis, in vitro drug release and dissolution analysis, bioequivalence determination, IVIVC model development and validation analysis for SUPAC changes or biowaiver applications, quantitative modeling and simulation analysis for small and large molecules from early to late drug development phase, drug-drug or drug-excipient interactions using transporter mediated IVIVE-PBPK model to understand drug absorption and oral bioavailability, DDIs (induction and competitive inhibition for liver, intestine, kidney) and pharmacogenomics in drug interactions.
DrShukla is on the Editorial Board of the Journal of Anticancer Research updates, serves as a peer reviewer for several journals, has published several highly cited research and review articles and has received patents and scientific awards from FDA and NIH. He has served on panels evaluating research grants submitted to NIH and FDA, mentored several undergraduate, graduate and post-doctoral trainees and currently serves as the lead instructor of the medical pharmacology course at the Foundation for Advanced Education in the Sciences (FAES) Graduate School, NIH.

Dr. Yogeshwar Bachhav is a Pharmacist by training. After completing PhD in Pharmaceutics from the Institute of Chemical Technology, Mumbai (Formerly UDCT), he worked in Europe (DACH region) for around 15 years with different start up and mid-size biotech and pharmaceutical companies.
During this tenure, he has successfully managed pharmaceutical development of several projects from POC to phase 1, 2 and 3 clinical trials. He has Strong network of Experts and CDMOs in EU, USA and Asia. In addition, he has 16 international publications, 8 patents and 30 conference proceedings to his credit. Recently he has edited a book for Wiley-VCH (Germany) on “Innovative Dosage Form, Design and Development at Early Stage”. Dr. Bachhav has been invited as a speaker for many international symposia around the globe (India, Europe and US).
He is a full time consultant with a German Biotech company -AiCuris Anti-infective Cures since 2014. There he is responsible to deal with pharmaceutical development of new drugs in anti-infectives segment.
In addition, Yogesh has founded a Pharmaceutical R&D consultancy firm – Adex Pharma in 2016. The prime objective of Adex is to resolve complex issues in the Pharmaceutical development of new drugs (INDs) and life cycle management of approved drugs (NDAs/ANDAs). He also supports few clients in India to resolve the CMC issues.
Dr. Bacchav is a member of the executive committee of Controlled Release Society-Indian Chapter.

Dr. Pisal graduated from Shivaji University in 1991 and completed his Masters (1993) and Ph D (2002) from Pune University. He has guided 30 Masters and 5 Ph D students from IIT Madras, Symbiosis International University and several other Indian Universities like Savitribai Phule Pune University, Bharati Vidyapeeth Deemed University, Tilak Maharashtra Vidyapeeeth. His research group has won five national awards for the best research from AICTE. He has successfully completed several R&D projects for AICTE and Pharma as well as Biotech industry (Ventri Biologicals, Lupin Ltd, Aristo). He was appointed UGC Professor for Innovative Programme in Pharmaceutical Biotechnology at Poona College of Pharmacy, Pune.
Dr. Pisal has been associated with Serum Institute of India Pvt. Ltd (SIPL) since 2007 and currently working as a Director of R&D and Manufacturing. He also leads Intellectual Property Cel at SIPL. His groups at Serum have collaborations for vaccine/mAb therapeutics development with MIT Boston, Oxford University UK, PATH US, NIBSC UK, MBL US, Kansas University US. At SIPL, his groups have contributed to development of Anticancer formulations for US market, Rotavirus vaccine (world’s first heat stable vaccine), Rabies vaccine, IND monoclonals like Rabies human monoclonal (first time in the world), Dengue monoclonal antibody, Pentavalent meningococcal conjugate vaccine and Injectable polio vaccine.
Dr. Pisal currently holds 26 Indian/International patents/applications encompassing formulation development, lyophilization, upstream/downstream process development for vaccines and mAbs and vaccine delivery. He is the author of 40 peer-reviewed journal articles. Dr Pisal, on behalf of SIIPL, received the globally coveted “United States Patent Office’s Patents for Humanity Award- 2018- Medicine Category” in Nov 2018. SIIPL IP Cell received coveted “IP Excellence Award (Life sciences) at Questel IP Executive Summit in Aug 2019. Dr. Pisal has been an invited expert for 1. Bill and Melinda Gates foundation for deciding funding strategy for vaccine projects, 2. Indian Council for Medical Research for filing IP on polio diagnostics and, 3. WHO / MSF for IP inputs on new vaccines for developing countries.